Trade Names:Albuminar-5- Injection 5%
Trade Names:Albuminar-25- Injection 25%
Trade Names:Albunex- Injection 5%
Trade Names:Albutein 5%- Injection 5%
Trade Names:Albutein 25%- Injection 25%
Trade Names:Buminate 5%- Injection 5%
Trade Names:Buminate 25%- Injection 25%
Trade Names:Human Albumin Grifols- Injection 25%
Trade Names:Plasbumin-5- Injection 5%
Trade Names:Plasbumin-25- Injection 25%
Maintains plasma colloid osmotic pressure and serves as carrier of intermediate metabolites in transport and exchange of tissue products.
Symptomatic relief and supportive treatment in management of shock, burns, hypoprothrombinemia, adult respiratory distress syndrome, cardiopulmonary bypass, acute liver failure, acute nephrosis, sequestration of protein-rich fluids, erythrocyte resuspension, hypotension or shock during renal dialysis, hyperbilirubinemia and erythroblastosis fetalis.
Severe anemia; cardiac failure; renal insufficiency; presence of normal or increased intravascular volume; chronic nephrosis; hypoprothrombinemic states associated with chronic cirrhosis; malabsorption; protein-losing enteropathies, pancreatic insufficiency; undernutrition.
Initial treatment usually consists of large amounts of crystalloid infusions (eg, normal saline, Lactated Ringer solution) with lesser amounts of 5% albumin to maintain adequate plasma volume. After first 24 h, ratio of albumin and crystalloid should maintain plasma albumin level of about 2.5 g ± 0.5 g/100 mL or total plasma protein level about 5.2 g/100 mL. This is best achieved with albumin 25% solution.
Normal Serum Albumin, 5%ShockGive as rapidly as necessary to improve patient's condition and restore normal blood volume.
AdultsIV Initial dose is 500 mL of 5% albumin given as rapidly as tolerated. If response in 30 min is inadequate, give additional 500 mL. In patients with slightly low or normal blood volume, rate is 2 to 4 mL/min.
ChildrenIV Rate of administration is 25% to 50% adult rate.
Newborns and infantsIV 10 to 20 mL/kg 5% albumin based on clinical response, BP, and assessment of anemia.
HypoproteinemiaTo replace protein loss, 5% albumin may be given.
Albumin Human, 25%Shock Adults and childrenIV Initial dose is determined by patient's condition and response to treatment. Therapy is guided by degree of venous or pulmonary congestion or Hct measurements.
Hypoproteinemia AdultsIV 50 to 75 g/day at rate not exceeding 2 mL/min.
ChildrenIV 25 g/day at rate not exceeding 2 mL/min.
Acute Nephrosis AdultsIV 100 mL 25% albumin in combination with loop diuretic repeated daily for 7 to 10 days.
Renal Dialysis AdultsIV Approximately 100 mL 25% albumin.
Hyperbilirubinemia and Erythroblastosis Fetalis Newborns and infantsIV 1 g/kg 1 to 2 h before transfusion.
Store at room temperature. Do not freeze.
None well documented.
None well documented.
Hypotension after rapid infusion (above 10 mL/min) or intra-arterial administration to patients undergoing cardiopulmonary bypass; rapid administration may cause vascular overload, dyspnea or pulmonary edema.
Allergic or pyogenic reactions (characterized by fever and chills).
Category C .
Undetermined.
Caution is needed because of added protein load.
Caution is needed because of added protein load.
Circulatory overload may develop in patients with CHF, renal insufficiency, or stabilized chronic anemia.
Relative anemia can be avoided by supplementing or replacing large quantities of albumin with whole blood.
Copyright © 2009 Wolters Kluwer Health.